JPMorgan raises target to USD 36.00 for Zai Lab stock

Published on 10/17/2026 at 22:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 106.31 million in the second quarter of 2026. Zai Lab stock was USD 23.19 on October 16, 2026, down 1.36 percent on Nasdaq.

Target and valuation

JPMorgan set a USD 36.00 target for Zai Lab on October 16, 2026.
Revenue reached USD 106.31 million in the second quarter of 2026.
Zai Lab stock last traded at USD 23.19 on October 16, 2026 at 4:00 p.m. ET, down 1.36 percent on Nasdaq.
Zai Lab had a negative P/E ratio of -13.60 as of October 16, 2026.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

JPMorgan raised its price target for Zai Lab from USD 27.00 to USD 36.00, according to Business Insider on October 16, 2026. The new target stands 55.24 percent above the Nasdaq price of USD 23.19. Zai Lab was last traded at USD 23.19 on October 16, 2026 at 4:00 p.m. ET, down 1.36 percent on Nasdaq.

Revenue reached USD 106.31 million

The latest reported operating figure is second-quarter revenue of USD 106.31 million. Yahoo Finance identifies the reporting period as the second quarter of 2026 and lists quarterly earnings of minus USD 50.83 million. The revenue figure gives the target revision a concrete operating backdrop, while the earnings number shows that profitability remains a central valuation issue.

Stock sits within its yearly range

Zai Lab's Nasdaq price stood 45.74 percent above its 52-week low of USD 15.96 and 22.10 percent below its 52-week high of USD 29.77 on October 16, 2026. The session opened at USD 24.19, reached a high of USD 24.19 and touched a low of USD 23.15. Trading volume was 843,206 shares against an average volume of 931,948 shares.

Valuation remains loss-making

The company had a market capitalization of USD 2.6 billion and a negative P/E ratio of -13.60 as of October 16, 2026. Zai Lab describes itself as a commercial-stage biopharmaceutical company focused on oncology, immunology, neuroscience and infectious diseases. Its investor-relations page identifies the primary listings as Nasdaq under ZLAB and Hong Kong under 9688.

Comparison with peers

Zai Lab (NASDAQ, USD): minus 1.36 percent, P/E -13.60, market capitalization USD 2.6 billion

BeiGene (NASDAQ, USD): P/E 3.73, market capitalization USD 20.2 billion

HUTCHMED (NASDAQ, USD): P/E 153.46, market capitalization USD 2.5 billion

What the target implies

The JPMorgan target is materially above the latest Nasdaq price, but the comparison sits alongside a negative earnings multiple and a second-quarter net loss. For investors, the next valuation question is whether revenue growth can translate into sustained profitability.

Nasdaq price closes the frame

The October 16, 2026 Nasdaq session ended with Zai Lab at USD 23.19, down 1.36 percent from the prior close of USD 23.51. The stock remained below its yearly high of USD 29.77 and above its yearly low of USD 15.96.